Rizobacter FY2025/26 Sales Surge 42% to $291B, EBITDA Up 65%

Argentine agro-input firm Rizobacter reported FY2025/26 sales of $291,000 million (Argentine pesos) and adjusted EBITDA of $29,094 million, up 42% and 65.2% respectively, despite a challenging market. The results follow a corporate restructuring and signal operational resilience, though the figures are nominal and likely influenced by high inflation. This is a company-specific earnings beat, not a macro signal.